Key features and details
- Goat polyclonal to Androgen Receptor
- Suitable for: WB, ELISA, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-Androgen Receptor antibody
See all Androgen Receptor primary antibodies
DescriptionGoat polyclonal to Androgen Receptor
Tested applicationsSuitable for: WB, ELISA, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Cow, Dog, Pig, Chimpanzee
- Human Brain and Human Heart lysates.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA
Concentration information loading...
PurityImmunogen affinity purified
Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Our Abpromise guarantee covers the use of ab19066 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.3 - 2 µg/ml. Detects a band of approximately 99 kDa (predicted molecular weight: 99 kDa).
A 1 hour primary incubation is recommended for this product.
|IHC-P||Use a concentration of 2 - 3 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionSteroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
Tissue specificityIsoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
Involvement in diseaseAndrogen insensitivity syndrome
Spinal and bulbar muscular atrophy X-linked 1
Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
Androgen insensitivity, partial
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR3 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
DomainComposed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
modificationsSumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
Cellular localizationNucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
- Information by UniProt
FormThere are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
- AIS antibody
- ANDR_HUMAN antibody
- Androgen nuclear receptor variant 2 antibody
ab19066 (2µg/ml) staining of paraffin embedded Human Prostate following steamed antigen retrieval with citrate buffer pH 6 and AP-staining shows nuclear staining in the secretory cells of the gland.
ab19066 (0.3ab19066 (0.3µg/ml) staining of Human Brain lysate (35µg protein in RIPA buffer) approx. 99kDa. Primary incubation was 1 hour. Detected by chemiluminescence.
µg/ml) staining of Human Brain lysate (35 µg protein in RIPA buffer) approx. 99kDa. Primary incubation was 1 hour. Detected by chemiluminescence.
Immunohistochemical analysis of paraffin-embedded Human prostate tissue, staining Androgen Receptor with ab19066 at 2 µg/ml. Antigen retrieval was performed by heat mediation in a citrate buffer (pH 6).
ab19066 has been referenced in 3 publications.
- Jin M et al. The effects of neuromedin S on the hypothalamic-pituitary-testicular axis in male pigs in vitro. Gen Comp Endocrinol N/A:N/A (2019). PubMed: 30981702
- McWhorter ES et al. LIN28B regulates androgen receptor in human trophoblast cells through Let-7c. Mol Reprod Dev 86:1086-1093 (2019). PubMed: 31215730
- Titus MA et al. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One 7:e30192 (2012). WB ; Human . PubMed: 22272301